In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...

Eli Lilly and Co. has received the Federal Drug Administration’s breakthrough therapy designation for a drug in development ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...

Investors in biotech companies approach their investments with the mindset of praying or scratching a lottery ticket because the success rate of new drug development is extremely low, and the costs ...

The drug is not considered a cure, but results emerging from clinical trials point to the first major advancement in decades for a devastating cancer.

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...